Prospects of the COVID-19 outbreak |
132 |
|
Q1. The expected date of the end of the current domestic COVID-19 epidemic |
|
|
|
May–June 2020 |
12.9 (7.6–18.9) |
|
|
July–August 2020 |
18.9 (12.9–25.8) |
|
|
September–December 2020 |
10.6 (5.3–16.7) |
|
|
After December 2020 |
47.7 (38.7–56.8) |
|
Q2. The expected date of the end of the current global COVID-19 pandemic |
|
|
|
May–June 2020 |
0 |
|
|
July–August 2020 |
6.8 (3.0–11.4) |
|
|
September–December 2020 |
9.8 (5.3–15.2) |
|
|
After December 2020 |
70.5 (62.9–78.0) |
|
Q3. The expected date of the occurrence of a second wave nationwide in South Korea |
|
|
|
Unlikely |
6.8 (3.0–11.4) |
|
|
May–June 2020 |
25.8 (18.9–33.3) |
|
|
July–August 2020 |
3.8 (0.8–7.6) |
|
|
September–December 2020 |
60.6 (52.3–68.2) |
|
|
After December 2020 |
3.0 (0.8–6.1) |
|
Q4. The expected date of the end of preventive measures to the inflow of COVID-19 into hospitals (e.g., operating COVID-19 screening clinics, safe clinics for respiratory patients, pre-emptive isolation for pneumonia, etc.) |
|
|
|
May–June 2020 |
26.5 (18.9–34.1) |
|
|
July–August 2020 |
14.4 (9.1–20.5) |
|
|
September–December 2020 |
5.3 (1.5–9.1) |
|
|
After December 2020 |
43.2 (34.8–51.5) |
|
|
Depends on the situation |
10.6 (6.1–15.9) |
|
Q5. The date of the termination of social distancing measures |
|
|
|
No longer needed |
1.5 (0–3.8) |
|
|
Within 4 weeks from nowa
|
45.5 (37.1–53.0) |
|
|
Within 4–8 weeks from nowa
|
7.6 (3.0–12.1) |
|
|
More than 8 weeks from nowa
|
37.1 (28.8–45.5) |
|
|
Depends on the situation |
8.3 (3.8–12.9) |
Preparation for a future COVID-19 outbreak |
132 |
|
Q1b. Crucial items that will be needed in hospitals in preparation for a second wave of COVID-19 |
|
|
|
N95 respirators |
70.5 (62.9–78.0) |
|
|
Isolation units (including negative-pressure units) |
42.4 (33.3–50.8) |
|
|
Hooded coveralls |
41.7 (33.3–50.7)) |
|
|
PAPR equipment (including hoods) |
32.6 (25.0–40.2) |
|
|
Professional COVID-19 physician |
25.0 (17.4–31.8) |
|
|
Professional COVID-19 nursing personnel |
25.0 (18.2–33.3) |
|
|
Infection control personnel |
15.2 (9.8–22.0) |
|
|
Other protective gear (goggles, hair caps, etc.) |
14.4 (9.1–20.5) |
|
|
Equipment for oxygen supplementation (including ventilators, high-flow O2) |
13.6 (8.3–19.7) |
|
|
Drugs for treatment (e.g., chloroquine, remdesivir, etc.) |
12.9 (7.6–18.9) |
|
|
Diagnostic equipment |
5.3 (1.5–9.8) |
|
|
Hand sanitizer |
1.5 (0–3.8) |
|
Q2. Necessity and possibility of reuse of N95 respirators within medical institutions in the case of a shortage |
|
|
|
Necessary and possible |
32.6 (25.0–41.6) |
|
|
Necessary and impossible |
42.4 (34.1–50.8) |
|
|
Not necessary and possible |
3.8 (0.8–7.6) |
|
|
Not necessary and impossible |
17.4 (11.4–24.2) |
|
Q3. Prioritization of patients in the case of a shortage of ventilators |
|
|
|
Severity of the disease |
21.2 (14.4–28.8) |
|
|
Probability of recovery |
47.0 (38.6–56.0) |
|
|
Life expectancy |
22.0 (15.2–29.5) |
|
|
Hospital arrival order |
2.3 (0–5.3) |
|
|
Not sure (difficult to answer) |
6.1 (2.3–10.6) |
|
Q4b. Key areas of research and development to encourage in preparation for a further spread of the COVID-19 pandemic |
|
|
|
Development of an effective vaccine |
75.0 (67.4–82.6) |
|
|
Development of an effective therapeutic agent |
56.8 (47.7–65.2) |
|
|
Development of rapid and accurate diagnostic testing methods |
52.3 (43.2–61.4) |
|
|
Development of an effective epidemiological investigation system |
32.6 (24.2–40.2) |
|
|
Establishing a clinical trial system that can verify reported therapeutic agents or new drugs |
28.8 (21.2–37.1) |
|
|
Development of mass supply methods for convalescent plasma from cured patients |
16.7 (10.6–23.5) |
|
|
Development of an effective self-isolation monitoring tool |
12.9 (7.6–18.9) |
|
|
Establishing a system for virus segregation |
10.6 (6.1–16.7) |
|
|
Development of an effective protective gear |
9.8 (4.5–15.9) |
|
|
Establishing animal experimental models that can verify reported therapeutic agents or new drugs |
4.6 (1.5–8.3) |
|
Q5a. Important policies to be implemented at the national level in preparation for another outbreak |
|
|
|
Securing national hospitals designated for the treatment of infectious diseases |
67.4 (59.1–75.8) |
|
|
Strengthening immigration or prohibiting entry from countries with an outbreak |
65.9 (57.6–73.5) |
|
|
Maintaining social distancing |
46.2 (37.9–55.3) |
|
|
Establishing a system for participation of private medical institutions/personnel in outbreaks |
45.5 (37.1–53.8) |
|
|
Reorganization of healthcare-related government |
22.7 (15.9–30.3) |
|
|
Securing masks, hand sanitizers |
22.0 (15.9–30.3) |
|
|
Securing community treatment centers |
18.9 (12.9–25.8) |
|
|
Activation of online education/conference systems |
8.3 (3.8–12.9) |
|
|
Full-fledge introduction of telemedicine |
3.0 (0.8–6.1) |
|
Q6c. Screening of asymptomatic individuals using RT-PCR tests to prevent hospital outbreaks |
|
|
|
Patients with a history of visiting areas with the outbreak |
88.6 (82.6–93.9) |
|
|
All patients who require hospitalization |
36.4 (28.8–44.7) |
|
|
All patients who need surgery |
27.3 (19.7–35.6) |
|
|
All patients who have recently been admitted to other hospitals |
29.5 (22.0–37.1) |
|
|
Medical staff treating COVID-19 patients |
31.1 (23.5–38.6) |
|
|
Screening of asymptomatic individuals is not required |
12.1 (6.8–17.4) |
|
Q7a. Measures that should be upheld even after the end of the current outbreak |
|
|
|
Thorough hand hygiene |
74.2 (65.9–81.8) |
|
|
Avoiding public spaces if one shows symptoms of infections, such as fever |
70.5 (62.9–78.0) |
|
|
Wearing masks in public |
56.8 (47.7–65.2) |
|
|
Informing hospitals of recent visits to risk areas or recent contact with patients with COVID-19 |
40.2 (32.6–48.5) |
|
|
Observe cough etiquette |
33.3 (25.0–42.4) |
|
|
Maintaining a 2-meter distance |
25.0 (18.2–32.6) |
|
|
Use of personal items, such as towels, tableware, mobile phones, etc. |
0 |
|
Q8. The best type of mask for use by the general public on a daily basis |
|
|
|
KF94 (or N95) mask |
13.6 (8.3–19.7) |
|
|
KF80 mask |
24.2 (16.7–31.8) |
|
|
Surgical mask |
53.8 (45.5–62.1) |
|
|
Face mask |
3.8 (0.8–6.8) |
|
|
Not recommended |
3.8 (0.8–6.8) |
The treatment of COVID-19 |
127 |
|
Q1b. Drugs that may be effective for the treatment of COVID-19 |
|
|
|
Remdesivir |
81.1 (74.0–88.2) |
|
|
Convalescent plasma |
66.9 (59.1–74.8) |
|
|
Hydroxychloroquine or chloroquine |
49.6 (40.2–58.3) |
|
|
Anti-HIV drugs (e.g., lopinavir/ritonavir) |
39.4 (31.5–47.2) |
|
|
Systemic corticosteroid |
22.8 (15.0–30.7) |
|
|
IL-6 pathway inhibitors (e.g., tocilizumab) |
15.7 (9.4–22.0) |
|
|
Macrolides (e.g., azithromycin) |
12.6 (7.1–18.9) |
|
|
Inhaled corticosteroid (e.g., ciclesonide) |
10.2 (5.5–15.7) |
|
|
Interferon |
1.6 (0–3.9) |
|
|
Oseltamivir |
0 |
|
Q2. Patients to be treated with hydroxychloroquine or chloroquine |
|
|
|
Q2-1. Asymptomatic, age < 60 years, no underlying disease |
26.8 (19.7–34.6) |
|
|
Q2-1. Moderate symptoms without pneumonia, age < 60 years, no underlying disease, SpO2 > 95% |
55.9 (47.2–64.6) |
|
|
Q2-2. Moderate symptoms without pneumonia, age ≥ 60 years, no underlying disease, SpO2 > 95% |
70.9 (63.0–79.5) |
|
|
Q2-3. Existence of pneumonia, SpO2 > 95% |
70.1 (61.4–78.0) |
|
|
Q2-4. Existence of pneumonia requiring oxygen therapy |
73.2 (65.4–81.1) |
|
|
Q2-5. The prevention of COVID-19 in elderly and patients with underlying diseases after exposure |
37.8 (29.1–45.7) |
|
|
Q2-6. The prevention of COVID-19 in medical staff treating COVID-19 patients |
22.8 (15.7–29.9) |
|
Q3. The appropriate duration of a hydroxychloroquine or chloroquine treatment regimen |
|
|
|
Within 5 days |
7.1 (3.1–11.8) |
|
|
5–7 days |
40.9 (32.3–48.8) |
|
|
8–10 days |
24.4 (17.3–32.3) |
|
|
11–14 days |
14.2 (7.9–20.5) |
|
|
15–21 days |
1.6 (0–3.9) |
|
|
Until negative conversion of virus detection |
3.9 (0.8–7.9) |
Miscellaneous |
132 |
|
Q1b. Important issues that require urgent resolution |
|
|
|
Determining the actual efficacy of existing or new drugs in the treatment of COVID-19 |
63.6 (55.3–71.2) |
|
|
The possibility of re-infection or the reactivation of the virus after patient recovery |
59.1 (50.8–67.4) |
|
|
The conditions underlying infection transmission (e.g., period of infection propagation) |
53.8 (44.7–62.9) |
|
|
The isolation criteria (e.g., inspection before release from isolation) |
36.4 (28.0–44.7) |
|
|
Efficacy of protective gear in preventing infection |
30.3 (22.0–38.6) |
|
|
Accuracy of existing diagnostic testing methods, including RT-PCR testing |
25.8 (18.9–32.6) |
|
|
Selection criteria for individuals to be examined and tested |
15.9 (9.8–22.7) |
|
|
Effectiveness of preventive medicine in the prevention of infection |
15.2 (9.1–22.0) |